List view / Grid view
The development of technology that can ‘see’ inside our bodies is one of the great achievements of modern medicine.1 For over 100 years, doctors have used imaging methods for this very reason to help guide patient care. Initially, two-dimensional x-ray pictures of bones and chests were used to help diagnose…
Mass spectrometry imaging allows direct measurement of the molecular composition of a sample. It can be used to image the spatial distribution of exogenous drugs and endogenous metabolites simultaneously over the surface of tissue sections or small biopsy, allowing new insights into both compound efficacy and safety during drug discovery.
The automated imaging and high-content imaging (HCI) markets are experiencing a widening dichotomy of users’ needs. Diverse hardware and software solutions are needed to bridge this divide...
This In-Depth Focus explores current uses and future development in mass spectrometry imaging for bringing new drugs to market...
Assay robustness tends to be the favoured descriptor when a particular assay can cope with minute changes in the sample, equipment, or operator. The more robust an assay, the more predictive data it ultimately yields. The industry’s greatest challenge for assay development has always been using those robust assays to…
This in-depth focus looks at improving assay techniques to produce more detailed results using crystallography. It also covers some aspects of high-content screening assay development that are critical to successful implementation...
Alzheimer’s disease (AD) is the most prevalent form of dementia.1 The common (>95% of cases) slow-developing form of the ailment is known as late-onset AD (LOAD) or sporadic AD (SAD). The rare (
Included in this issue: The importance of industry partnerships; Calcilytics as potential novel therapeutic treatments to halt Alzheimer's disease; Accelerating neuroscience research with flow cytometry...
"Well thought through and brilliantly executed" study shows different DNA-repair mechanism in embryos compared to iPSCs
Rheumatoid arthritis (RA) is joint-related, immune-based inflammatory disarray that affects almost 1% of the world’s population. The most evidenced pathogenesis is T-cell activation, which leads to clusters of differentiation (CD) in the T-cells and concurrently increases various inflammatory biomarkers.
The screening of drug targets against compound libraries is now a mature and validated approach to identifying the chemical starting points of drugs...
Drug resistance is a significant therapeutic problem, from infectious diseases to cancer. Given a large enough population of genetically varying target cells, the emergence of drug resistance is not surprising and is even unavoidable...
Recognised as the next wave of medicine, cell therapies have made significant strides over the last several years. But such advancements can present unique challenges, especially as more products move out of the clinic and toward commercialisation. And unlike typical pharmaceuticals, cell therapies rely heavily on the manufacturing process to…
Drug Target Review editor Steve Bremer asks David F Fischer for his views on target discovery and validation in drug discovery. David F Fischer, PhD, is Executive Director Biology at Charles River...
A range of drugs used in modern medicine are derived from animal venoms, and Steve Trim from Venomtech discusses how natural selection has made venoms particularly useful tools for uncovering new targets in drug discovery...
